New drug combo shows promise for esophageal cancer before surgery

This study tests whether giving two drugs—camrelizumab (an immunotherapy) and palbociclib (a targeted therapy)—before surgery can safely shrink tumors in people with esophageal cancer that can be removed. About 41 adults with resectable esophageal squamous cell carcinoma will receive the combination before their operation. The main goal is to see how many patients have a major response (fewer than 10% live tumor cells left) and to check for side effects.